<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758897</url>
  </required_header>
  <id_info>
    <org_study_id>VG161-C101</org_study_id>
    <nct_id>NCT04758897</nct_id>
  </id_info>
  <brief_title>Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of VG161 in Subjects With Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CNBG-Virogin Biotech (Shanghai) Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CNBG-Virogin Biotech (Shanghai) Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This Phase I study&#xD;
      will be conducted in HSV-seropositive subjects with advanced malignant solid tumors that are&#xD;
      refractory to conventional therapies. This is an open label study to determine the safety and&#xD;
      tolerability of VG161, and recommended dose of VG161 for Phase II trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be conducted in 7 dose ascending cohorts, including 3 single dose accelerated&#xD;
      titration design pilots and 4 multiple dose escalation groups.&#xD;
&#xD;
      Descriptive statistics will be used to summarize all data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD/RP2D</measure>
    <time_frame>1 month</time_frame>
    <description>MTD (Maximum tolerable dose) / RP2D (Recommended dose for phase II)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurence of DLT</measure>
    <time_frame>1 month</time_frame>
    <description>Occurence of DLT (Dose Limiting Toxicity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Numbers of DLT</measure>
    <time_frame>1 month</time_frame>
    <description>Numbers of DLT (Dose Limiting Toxicity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurence of AE and SAE（NCI CTCAE 5.0）</measure>
    <time_frame>7 months</time_frame>
    <description>Occurence of Adverse Event (AE) and Serious Adverse Event (SAE) （NCI CTCAE 5.0）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of AE and SAE（NCI CTCAE 5.0）</measure>
    <time_frame>7 months</time_frame>
    <description>Frequency of Adverse Event (AE) and Serious Adverse Event (SAE) （NCI CTCAE 5.0）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax(h)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Time to peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(copies/ugDNA)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate Objective Response Rate by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate Disease Control Rate by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mPFS</measure>
    <time_frame>7 months</time_frame>
    <description>Evaluate medium Progression Free Survival by RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD3+, CD4+, CD8+</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of CD3+, CD4+, CD8+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL15</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of IL15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1, PD-1</measure>
    <time_frame>7 months</time_frame>
    <description>Concentration of PD-L1, PD-1,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Existence of Biomarkers</measure>
    <time_frame>4 months</time_frame>
    <description>PD-L1, Nectin2, HVEM</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Advanced Malignant Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5.0*10^7 on D1&#xD;
1.0*10^8 on D1&#xD;
2.0*10^8 on D1&#xD;
2.0*10^8 on D1 and D2&#xD;
2.0*10^8 on Days 1 to 3&#xD;
2.0*10^8 on Days 1 to 4&#xD;
2.0*10^8 on Days 1 to 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))</intervention_name>
    <description>Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>VG161</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females aged within 18 to 80 years.&#xD;
&#xD;
          2. Subject with late stage carcinoma which is refractory/relapsed after and/or intolerant&#xD;
             of standard therapies or for which no standard therapy exists.&#xD;
&#xD;
          3. There is at lease one injectable tumor lesion that meet the requirements of the&#xD;
             assigned dose level. The superficial lesions are preferred, and the deep lesions that&#xD;
             can be injected under the guidance of B ultrasound or computed tomography (CT) scan&#xD;
             can also be selected.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) scores 0 or 1.&#xD;
&#xD;
          5. Life expectancy is at least 3 months.&#xD;
&#xD;
          6. Required organ function:&#xD;
&#xD;
        1) Hematology blood (no blood transfusion or colony stimulating factor treatment within 14&#xD;
        days): Absolute neutrophil count (ANC)≥1.5×10^9L, Platelets ( PLT)≥75×10^9L, hemoglobin&#xD;
        (Hb)≥85g/L; 2) Liver function: Total Serum bilirubin (TBIL)≤1.5×ULN (the upper limit of the&#xD;
        reference range), Alanine aminotransferase (ALT)≤3×ULN, aspartate aminotransferase&#xD;
        (AST)≤3×ULN (acceptable for patients with liver metastasis or liver cancer: TBIL≤5×ULN,&#xD;
        AST≤5×ULN, ALT≤5×ULN); 3) Renal function: Serum creatinine≤1.5×ULN, and creatinine&#xD;
        clearance≥50 ml/min (calculated per Cockcroft-Gault formula); 4) Coagulation function:&#xD;
        activated partial thromboplastin time (APTT)≤1.5×ULN, international standardized ratio&#xD;
        (INR)≤1.5×ULN.&#xD;
&#xD;
        7. Subjects of childbearing potential (male and female) must agree to use a reliable&#xD;
        contraceptive method (hormone or barrier method or abstinence) during the study and for at&#xD;
        least 90 days following the last dose; females of childbearing potential must have a&#xD;
        negative blood or urine pregnancy test within 7 days of study enrollment.&#xD;
&#xD;
        8. Signed written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject in prior anti-tumor therapies such as chemotherapy, radiotherapy, biotherapy,&#xD;
             endocrinotherapy, targeted therapy, immunotherapy within 4 weeks of study treatment&#xD;
             initiation.&#xD;
&#xD;
          2. Participation in clinical trials of any other investigational agents within 4 weeks of&#xD;
             study treatment initiation.&#xD;
&#xD;
          3. Major organ surgery (excluding puncture biopsy) or significant trauma within 4 weeks&#xD;
             of study treatment initiation.&#xD;
&#xD;
          4. Patients who received systemic treatment with either corticosteroids ( &gt;10 mg/ daily&#xD;
             prednisone or equivalent) or other immunosuppressive medications within 14 days of&#xD;
             study treatment initiation.&#xD;
&#xD;
          5. Subjects with any ≥Grade 1 toxicity (as per NCI CTC AE Version 5.0) related to prior&#xD;
             anti-cancer therapy (except for toxicity that the investigator assessed to be no&#xD;
             safety risk, such as alopecia.).&#xD;
&#xD;
          6. Subjects with any uncontrolled active Central Nervous System (CNS) metastasis or&#xD;
             meningeal metastasis with clinical symptoms.&#xD;
&#xD;
          7. Seronegative for Herpes Simplex Virus (HSV) (HSV-1IgG and HSV-1IgM).&#xD;
&#xD;
          8. Subjects with the relapse of HSV infection and relevant clinical manifestations, such&#xD;
             as lip herpes, herpes keratitis, herpes dermatitis, and genital herpes.&#xD;
&#xD;
          9. Subjects with other uncontrolled active infections.&#xD;
&#xD;
         10. Known history of immunodeficiency and test positive of human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
         11. Active infection of hepatitis B (HBV) (hepatitis b virus titer higher than the&#xD;
             detection limit or those requiring antiviral therapy), or hepatitis C virus (HCV).&#xD;
&#xD;
         12. History of severe cardiovascular disease:&#xD;
&#xD;
        1)Ventricular arrhythmias requiring clinical intervention; 2)QTc interval &gt;480 ms; 3)Acute&#xD;
        coronary syndrome, congestive heart failure, stroke or other cardiovascular events of III&#xD;
        grade or above within 6 months; 4)The cardiac function grade≥II or left ventricular&#xD;
        ejection fraction (LVEF) &lt;50% per the New York Heart Association (NYA); 5)Uncontrolled&#xD;
        hypertension. 13. Subjects with active or past autoimmune diseases that are likely to recur&#xD;
        (e.g. systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.); acceptable for&#xD;
        patients with clinically stable autoimmune thyroiditis.&#xD;
&#xD;
        14. Subjects with any prior ≥Grade 3 immune-related adverse event (irAE) while receiving&#xD;
        any previous immunotherapy agent.&#xD;
&#xD;
        15. known to have alcohol or drug dependence. 16. Persons with mental disorders or poor&#xD;
        compliance. 17. Pregnant or lactating women. 18. Subjects with any significant unrelated&#xD;
        systemic illness that to the investigator's opinion would compromise the subject's&#xD;
        eligibility to participate the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, doctor</last_name>
    <phone>13761222111</phone>
    <email>lijin@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>ShangHai East hospital</name>
      <address>
        <city>ShangHai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xin Hua Hospital Affiliated to ShangHai Jiao Tong University School of Medicine</name>
      <address>
        <city>ShangHai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Shen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

